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ABSTRACT 
Mendelian adult-onset leukodystrophies are a spectrum of rare inherited progressive 
neurodegenerative disorders affecting the white matter of the central nervous system . 
Among these, Cerebral Autosomal Dominant and Recessive Arteriopathy with Subcortical 
Infarcts and Leukoencephalopathy (CADASIL and CARASIL), Cerebroretinal vasculopathy 
(CRV), Metachromatic leukodystrophy (MLD), Hereditary diffuse Leukoencephalopathy with 
spheroids (HDLS), Vanishing white matter disease (VWM) present with rapidly progressive 
dementia as dominant feature and are caused by mutations in NOTCH3, HTRA1, TREX1, 
ARSA, CSF1R, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, respectively. Given the rare incidence 
of these disorders and the lack of unequivocally diagnostic features, leukodystrophies are 
frequently misdiagnosed with common sporadic dementing diseases such as Alzheimer’s 
disease (AD), raising the question of whether these overlapping phenotypes may be 
explained by shared genetic risk factors. To investigate this intriguing hypothesis, we have 
combined gene expression analysis 1) in 6 different AD mouse strains (APPPS1, HOTASTPM, 
HETASTPM, TPM, TAS10 and TAU), at  5 different developmental stages (Embryo [E15], 2 
months, 4 months, 8 months and 18 months), 2) in APPPS1 primary cortical neurons under 
stress conditions (oxygen-glucose deprivation) and single-variant and single-gene (c-alpha 
and SKAT tests) based genetic screening in a cohort composed of 332 Caucasian late-onset 
AD patients and 676 Caucasian elderly controls. Csf1r was significantly overexpressed 
(Log2FC>1, adj. p-val<0.05) in the cortex and hippocampus of aged HOTASTPM mice with 
extensive Aβ core dense plaque pathology. We identified 3 likely pathogenic mutations in 
CSF1R TK domain (p.L868R, p.Q691H and p.H703Y) in our discovery and validation cohort, 
composed of 465 AD and MCI Caucasian patients from the UK. Moreover, NOTCH3 was a 
significant hit in the c-alpha test (adj p-val = 0.01). Adult onset Mendelian leukodystrophy 
genes are not common factors implicated in AD. Nevertheless, our study suggests a 
potential pathogenic link between NOTCH3, CSF1R and sporadic LOAD, that warrants further 
investigation. 
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1. INTRODUCTION 
Mendelian adult-onset leukodystrophies are a spectrum of rare chronic progressive 
disorders affecting the white matter of the central nervous system. Although a growing 
body of literature is reporting newly discovered forms, the most characterized adult-onset 
leukodystrophies are Cerebral Autosomal Dominant and Recessive Arteriopathy with 
Subcortical Infarcts and Leukoencephalopathy (CADASIL and CARASIL), Cerebroretinal 
vasculopathy (CRV), Metachromatic Leukodystrophy (MLD), Hereditary diffuse 
Leukoencephalopathy with spheroids (HDLS), Vanishing white matter disease (VWM), 
caused by mutations in NOTCH3, HTRA1, TREX1, ARSA, CSF1R, EIF2B1, EIF2B2, EIF2B3, 
EIF2B4, EIF2B5, respectively (Joutel et al., 1996), (Hara et al., 2009), (Richards et al., 2007), 
(Fluharty et al., 1991), (Rademakers et al., 2011), (Scali et al., 2006). Given the rare incidence 
of these disorders (5/100 000 to only few cases reported), the lack of peculiar and 
distinctive 1) clinical features, generally represented by rapidly progressive dementia, 
behavioural changes, pyramidal and extrapyramidal signs and, less commonly, ischemic 
strokes and epileptic seizures; 2) MRI lesion patterns, normally characterized by T2-
weighted periventricular and subcortical, patchy and later confluent white matter 
hyperintensities with prominent frontal involvement,  and 3) neuropathological features, 
frequently a combination of diverse neurodegenerative hallmarks, these rare Mendelian 
disorders are most frequently underrecognized and misdiagnosed with common sporadic 
dementias such as Alzheimer´s disease (AD). On the other hand, motor features like  ataxia 
and spasticity may appear in the course of AD progression, particularly in the cases caused 
by or associated to PSEN1 mutations (Rossor et al., 2010) and AD patients may display MRI 
patterns and neuropathological features typical of adult-onset leukodystrophies (Smith et 
al., 2000) (Marnane et al., 2016) (Barber et al., 1999)(Guerreiro et al., 2013), suggesting a 
potential common pathogenic ground. 
In the past 10 years, Next Generation Sequencing (NGS) paved the way for groundbreaking 
discoveries in AD, showing that Mendelian rare disorders offer a unique window into the 
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sporadic complex traits and, particularly, that rare alleles in TREM2, TYROBP and NOTCH3, 
causative for adult-onset leukodystrophies, significantly influence the susceptibility for AD 
(Guerreiro et al., 2013) (Ma et al., 2015) (Guerreiro et al., 2012). Moreover, the sequencing 
of different mouse strains showed extensive similarities  between mouse and human 
genome and validated the importance of using mouse models to illuminate the genetics of 
human diseases (Cheng et al., 2014)
, 
(Yue et al., 2014)
 
. Nevertheless, NGS still presents 2 
main challenges: 1) the huge amount of data generated is difficult to mine and 2) the 
investigation of rare coding variants requires several thousands of samples. Consequently, 
the need for experimental methods that accurately identify critical genes and strategies to 
empower association studies became priorities. Therefore, we have applied a combination 
of cortical and hippocampal gene expression analysis in 6 diverse AD mouse strains (APPPS1, 
HOTASTPM, HETASTPM, TPM, TAS10 and TAU), at 5 different developmental stages 
(embryo [E15], 2 months, 4months, 8months and 18 months) to comprehensively study 
leukodystrophy gene expression pattern in relation to the progression of AD 
neuropathology and under stress conditions such as oxygen-glucose deprivation (OGD), 
which represents an in vitro model of ischemic stroke, a common feature in several adult-
onset leukodystrophies and frequent comorbidity in AD. We then used exome and genome 
sequencing data in a cohort composed of 332 Caucasian late-onset AD patients and 676 
Caucasian elderly controls to investigate rare coding variability in these main adult-onset 
Mendelian leukodystrophy genes. Among the studied genes, Csf1r was the only gene 
significantly overexpressed (Log2FC>1, p-val<0.05) in AD mouse models and its expression 
tightly correlated with the severity of core dense plaque deposition. Moreover, we 
identified a total of 3 rare variants in CSF1R tyrosine kinase (TK) domain and TK flanking 
regions (p.L868R and p.D565N,  p.G957R, respectively)  present only in cases and very likely 
pathogenic. We then screened CSF1R in an independent cohort composed of 465 MCI and 
AD cases, identifying 2 additional mutations in CSF1R TK domain (p.Q691H and p.H703Y). 
Finally, NOTCH3 was a significant hit in the gene-based analysis (adj p-value=0.01), 
suggesting a potential role as disease modifier. We conclude that rare coding variability in 
adult-onset Mendelian leukodystrophy genes is not a common risk factor for AD. However, 
CSF1R coding variants clustering in the TK domain and NOTCH3 may influence AD 
susceptibility.  
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2. MATERIALS AND METHODS 
Adult-onset Leukodystrophy gene selection 
The selected genes are all Mendelian leukodystrophy causative genes with a core clinical 
hallmark represented by adult-onset subacute dementia with frontal predominance 
revealed by T2 weighted magneto resonance imaging (MRI) (Table S1). Moreover, all of 
these candidate genes present more than one of the following features:  1) previously 
reported misdiagnosis with Alzheimer’s disease (CADASIL, HDLS, RVCL, MLD) (Guerreiro et 
al., 2012) (Rademakers et al., 2011) (Richards et al., 2007) (Johannsen et al., 2001); 2) 
molecular interaction with other genes playing a key role in AD (NOTCH3, CSF1R) (Thijs et 
al., 2003) (Otero et al., 2009); 3) genes taking part to APP-Aβ metabolism (NOTCH3, 
HTRA1)(Grau et al., 2005), 4) co-presence of AD neuropathological hallmarks reported 
(NOTCH3 and CSF1R)(Paquet et al., 2010) (Baba et al., 2006) and 5) most frequently 
mutated genes in adults with leukoencephalopathies (NOTCH3, EIF2B4, EIF2B5, CSF1R) 
(Lynch et al., 2017). 
The pipeline followed in this study is described in Fig 1. 
Gene expression analysis 
We have used microarray data publicly available (MouseAC database 
[http://www.mouseac.org/])(Matarin et al., 2015) and real-time PCR data to  analyze  Arsa, 
Csf1r, Eif2b1, Eif2b2, Eif2b3, Eif2b4,  Eif2b5, Htra1, Notch3 and Trex1 gene expression 1) in 
the hippocampus and cortex of 6 different AD mouse strains (APPPS1, HOTASTPM, 
HETASTPM, TPM, TAS10 and TAU), 2) at 5 different time points (embryonic development 
[E15], 2 months, 4 months, 8 months and 18 months), to comprehensively follow 
expression changes related to Aβ plaques density (HOTASTPM, HETASTPM and TAS10), 
neurofibrillary tangles (TAU) and absence of pathology (E15, TPM). Adult APPPS1 data for 
hippocampus were available only for 2 months of age, where no plaques were reported but 
only rare Aβ oligomers in cortex and surrounding cortical vessels (Fig. S1). Finally, 
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considering that ischemic stroke is a common feature in several leukodystrophies and 
frequent comorbidity in AD, we used an in vitro model of ischemic stroke and performed 
OGD experiments in APPPS1 primary cortical neurons to test whether leukodystrophy gene 
expression pattern may have significantly differed between APPPS1 and WT mice under 
stress conditions 
 
 
Genetic screening 
The discovery cohort  
The discovery cohort was composed of 332 apparently sporadic AD cases and 676 elderly 
controls, neuropathologically and clinically confirmed, originating from the UK and North 
America. The mean age at disease onset was 71.66 years (range 41-94 years) for cases and 
the mean age of ascertainment was 78.15 years (range 60-102 years) for controls. The 
majority of the cases (77%) were late-onset (> 65 years at onset). Among the cases and 
controls, 42% and 51% were female, respectively. 58% and 47% of the cases and controls 
carried the APOE ε4 allele, respectively. The APOE ε4 allele was significantly associated to 
the disease status in the NIH and ADNI series (p-value= 0.02 and 1.19x10E-9, respectively). 
This cohort has already been described elsewhere (Sassi et al., 2016) . The threshold call 
rate for inclusion of the subject in analysis was 95%. On this cohort we performed 1) gene-
based analysis (SKAT and c-alpha tests) and 2) single-variant association analysis. Finally, we 
followed-up, in an independent Caucasian dataset, CSF1R, the only gene significantly 
overexpressed during AD most severe pathology (Figure 1, Table S2).  
The follow-up dataset  
The follow-up dataset was composed of 296 AD and 169 MCI late-onset cases (mean age at 
onset >75y) from UK (Table S2). Written informed consent was obtained for each clinically 
assessed individual and the study was approved by the appropriate institutional review 
boards. All samples had fully informed consent for retrieval and were authorized for 
ethically approved scientific investigation (UCLH Research Ethics Committee number 
10/H0716/3, BYU IRB, Cardiff REC for Wales 08/MRE09/38+5, REC Reference 04/Q2404/130, 
National Research Ethics Service [NRES]). 
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Exome and genome sequencing  
DNA was extracted from blood or brain for cases and brain only for controls using standard 
protocols. Library preparation for next generation sequencing was based on Roche 
Nimblegen Inc. or TruSeq, Illumina protocols and has been described elsewhere (Sassi et al., 
2016).Genome sequencing was performed in 199 controls, from the Cache County Study on 
Memory in Aging. All samples were sequenced with the use of Illumina HiSeq technology.  
Sequence alignment and variant calling were performed against the reference human 
genome (UCSC hg19) and has been described in the eMaterials. 
Initial analysis excluded pathogenic mutations in APP, PSEN1, PSEN2, MAPT, GRN and 
TREM2. All variants within the coding regions of the 10 adult-onset leukodystrophy 
candidate genes (ARSA [NM_000487]; CSF1R [NM_005211]; EIF2B1 [NM_001414]; EIF2B2 
[NM_014239]; EIF2B3 [NM_001261418]; EIF2B4 [NM_001034116]; EIF2B5 [NM_003907]; 
HTRA1 [NM_002775]; NOTCH3 [NM_000435] and TREX1 [NM_016381] have been collected 
and analysed, including 20.8 Megabase pairs (Mbs) of coding sequence. 
Sanger sequencing 
Mutations in CSF1R TK domain and flanking regions were validated with Sanger Sequencing. 
CSF1R was screened in an additional follow-up cohort composed of 296 AD and 169 MCI 
cases (Supplementary Materials and Methods). 
 
Statistical Analysis 
In the single-variant analysis, allele frequencies were calculated for each low frequency 
and rare coding variants in cases and controls and Fisher’s exact test on allelic association 
was performed. The threshold call rate for inclusion of the subjects and genetic variants in 
analysis was 95%.  MouseAC data have been analyzed and FDR correction was applied. 
The Supplement provides a more detailed description of the methods used (mouse and 
human gene expression analysis, oxygen-glucose deprivation experiments, sanger 
sequencing, statistical analysis and bioinformatics). 
 
3. RESULTS 
Gene expression analysis 
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We do not report any significant differential expression in Arsa, Csf1r, Eif2b1, Eif2b2, Eif2b3, 
Eif2b4,  Eif2b5, Htra1, Notch3 and Trex1 until the development of severe AD pathology, 
markedly pronounced in the most aggressive AD strain studied, HOTASTPM, homozygous 
for the Swedish mutation APP p.K670N/M671L and PSEN1 p.M146V, 8 months of age (Fig. 
2a-d, Table S3 and S4). Here, Csf1r was up to 2 folds significantly overexpressed both in the 
hippocampus and cortex (Log2FC=1.2 and 1.1; adj p-value= 2.5e-07 and 8.7E-05, 
respectively) and presented a trend at 18 months both in hippocampus and cortex 
(Log2FC=0.75 and 0.98; adj p-value= 2.7e-04 and 3e-04, respectively), in linear correlation 
with the most rapid and severe core dense plaque deposition (0.8 core-dense plaque/month 
and 0.5 core-dense plaque/month between 4m-8m and 8m-18m of age, respectively)( 
http://www.mouseac.org/)(Fig2a-d, Table S3 and S4). Moreover, Csf1r overexpression 
positively correlated also with tau pathology, suggesting that Csf1r upregulation is not Aβ 
plaque specific.  By contrast, Csf1r was downregulated when plaque deposition was minimal 
(HETTAS10TPM, TAS10, TPM and TAU, 2m; TAS10 and TAU, 4m) (Table S3 and S4). 
Importantly, Csf1r upregulation relied on microglia infiltration and was co-expressed with 
other microglia markers such as Aif1, CD68, Trem2, Tyrobp and Grn. Particularly, Csf1r and 
Grn displayed the same pattern of overxpression, which was between one third to one 
fourth of Tyrobp and Trem2 overall upregulation (Fig. 3, Table S3 and S4). 
Embryonal hippocampi and Primary neuronal cortical cultures oxygen glucose deprivation 
(OGD) experiments 
We do not report any significant differential expression in the studied genes between 
APPPS1 and WT embryonal hippocampi and in APPPS1 and WT primary cortical neurons 
after OGD experiments (Table S5). This is likely due to the fact that most of the 
leukodystrophy genes are expressed on microglia, only moderately present in E15 
hippocampal neurons and in primary neuronal cortical cultures. In line with this 
observation, Csf1r and its ligands (Csf1 and Il34),  Grn, Trem2 and Aif2 were significantly 
overexpressed in both APPPS1 and WT adult hippocampi compared to the embryonal ones 
(Log2FC=4, 2.45, 7.9, 1.5, 2.24, 3.4 and 4.2, 2.7, 7.9, 1.77, 3.1 and 3.8, respectively)(Table 
S5). By contrast, Notch3 was up to 2 folds upregulated in both APPPS1 and WT embryonal 
hippocampi compared to adult hippocampi. 
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Moreover, we noticed that TREX1 5’UTR displays the typical features of many  transcripts, 
like BACE1,  that are translationally controlled by cellular stress (O’Connor et al., 2008): 
TREX1 5’UTR  is indeed particularly long (628nts), GC-rich (65%) and predicted to contain 6 
upstream open reading frames (uORFs)(http://www.ncbi.nlm.nih.gov/orffinder/) (Fig. 
S2a,b), suggesting TREX1 transcript might be a target of translation control by one or more 
stress-activated pathway. Therefore, we have investigated TREX1 protein levels in both 
APPPS1 and WT adult brains and we do not report any macroscopically significant difference 
(Fig. S2cI-IV). This may be due to the fact that APPPS1 mice used for these experiments, 
being 2 months of age, did not display a severe pathology (Fig. S1).  
Genetic screening 
The study population consisted of a total of 332 sporadic and mainly late-onset AD cases 
and 676 elderly controls of British and North American ancestry. 
We do not report any pathogenic mutation in APP, PSEN1 and PSEN2 in our cohort. 
However, one of the controls was a heterozygous carrier of the protective variant APP 
p.A673T (MAF 7x10E-4 in our cohort and MAF 5x10E-4 among the European non-Finnish, 
ExAC database, released 13 January 2015). 
We performed a single-variant and a single-gene association analysis in a pre-defined set of 
adult-onset Mendelian Leukodystrophy genes (ARSA, CSF1R, EIF2B1, EIF2B2, EIF2B3, EIF2B4, 
EIF2B5, HTRA1, NOTCH3, TREX1) including 20.8 Megabase pairs (Mbs) of coding sequence. 
A total of 215 single nucleotide variants (SNVs) has been identified. Among these, 77(35.8%) 
were nonsynonymous, 59 (27.4%) were synonymous, 13 (6%) UTR variants. Among the 
missense variants, 192 (95%) were very rare (MAF<1%), 16 (7.9%) were low frequency 
(1%<MAF<5%) and 12(5.9%) were common (MAF>5%). In addition, we report 4 novel coding 
variants (NOTCH3, p.A2146E, CSF1R p.G957R and p.D565N and ARSA p.H425Y) . Variant 
minor allele frequency and novel variants were based on ExAC database, European non-
Finnish panel and EVS European-American panel, released March 14, 2016, or dbSNP 137 
(Table S6) 
The overall variant frequency in our cohort was in line with the variant frequency reported 
in the American-European cohort in the Exome Variant server database (Table S7). 
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Single-gene based analysis 
We carried out gene-wide analysis to combine the joint signal from multiple variants (coding 
variants and flanking UTRs) within a gene and to provide greater statistical power than that 
for single-marker tests. All the variants (nonsynonymous, synonymous, UTRs, singletons) 
located within the studied genes and their exon-intron flanking regions were collapsed 
together and their combined effect was studied. 
NOTCH3 is the only significant hit in the c-alpha test (adj p-value= 0,01) (Table S8a). The 
signal is driven by a common coding synonymous variant (p.P1521P) of moderate effect size 
(OR= 1.755, CI= 1,31-2,33), significant after Bonferroni correction (adj p-value= 0.02) (Table 
S9). TREX1 was another hit in the c-alpha test, although nominally significant (adj p-value= 
0.56) and the signal is mainly driven by a 5’UTR and synonymous (p.Y232Y) variants (Table 
S8a and Table S9). None of these variants were predicted to affect the splicing site 
(http://www.umd.be/HSF/) or a miRNA binding site 
(http://www.microrna.org/microrna/home.do).  
Single-variant based analysis 
A total of 69 rare and low frequency coding missense mutations was considered in the 
single-variant based analysis in the studied genes. Among these, the majority (62.8%) were 
singletons (Table S10) 
Moreover, 41 missense variants (59.4%) were described as damaging variants by at least 2 
out of 3 in silico prediction softwares (SIFT, Polyphen and Mutation Taster).  
The study possessed relatively low power to detect a significant association between cases 
and controls for low frequency and rare variants, however we analyzed these variants 
because we could not preclude the possibility that high effect risk alleles were present. 
EIF2B4 and CSF1R harbour the lowest and highest relative frequency of low frequency and 
rare coding variants (mean= 1.27 and 5.13 low freq-rare variant per kb of coding sequence, 
respectively), with 81.25% of the rare and low frequency coding variability in CSF1R 
clustering in the Ig-like domain (Table S11-S10). 
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The main hits, although not significant, are rare variants with moderate to strong effect 
sizes (0.6<OR<2.73) clustering  to EIF2B4, NOTCH3, TREX1 and CSF1R (Table S10). 
None of the missense mutations leads to a premature stop codon.  
Singletons in CSF1R TK domain 
We report 2 heterozygous missense mutations in the CSF1R TK domain (exons 12-22, aa 
582-910) in the discovery cohort (p.L868R and p.E694K), detected in one case and one 
control, respectively. Moreover, we found 4 likely pathogenic variants in the TK domain 
flanking regions (aa 538-581 and 911-972): CSF1R p.D565N, p.E916K, p.E920D, p.G957R . We 
then screened CSF1R in an independent follow-up cohort of late-onset AD and MCI patients 
and we identified 2 additional mutations in CSF1R TK domain (p.Q691H and p.H703Y) (Table 
1). 
CSF1R TK mutation carriers (Patient E, F and H) presented a rather homogeneous phenotype 
(Table 2). All these carriers were LOAD cases displaying memory impairment at onset. 
Behavioural and motor signs eventually appeared. In 2/3 patients cardiovascular problems 
and strokes preceded the dementia. The neuropathology examination, available for Patient 
H and I, showed aggressive and diffuse neurodegeneration (Braak 6 and Cerad C) . Two out 
of three carriers were heterozygous for APOE ε4 allele and do not report any familial history 
for dementia. By contrast, Patient H was homozygous for APOE ε4 allele, had a family 
history for dementia (4 brothers) and plausibly the combination of these risk factors, likely 
coupled with a pre-existent cerebrovascular disorder, may explain the earlier age at onset 
compared to the other patients (64 years). Patient I carried a missense mutation in CSF1R TK 
flanking region (p. G957R) and displayed a different clinical picture, dominated by early-
onset dementia (49y) and language problems at onset. Although the small sample size, we 
do not report any association between age at onset, severity of the disease progression and 
disease duration. 
Detailed clinical description was available for 4 patients. The clinical, neuroimaging and 
neuropathological features of the carriers are summarized in Table2. 
 
Patient H (c.2603T>G; L868R) 
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This male patient was born in 1932 and deceased aged 75 years. He was one of five siblings 
who all survived to old age, of which four experienced memory problems or received a 
diagnosis of dementia or AD. The informant reported he experienced sudden decline 
following a stroke at 65 years. He had obvious short-term memory problems and dysphasia. 
At this stage, he was considered to have probable vascular dementia. Pathological 
examination of the brain concluded this patient had a high probability of AD. Neurofibrillary 
tangle stage was consistent with Braak stage VI while plaque pathology met CERAD criteria 
for score C. In addition, there was evidence of amyloid angiopathy, focal TDP-43 positivity 
and occasional glial inclusions. 
 
 
Patient E (p.Q691H) 
This patient was born in 1922 and deceased aged 89 years. She complained of memory 
problems aged 82 and 2 years later underwent a MRI scan, which showed symmetric patchy 
periventricular hyperintensities, mainly pronounced in the frontal lobe (Figure 4a). 
Following annual visits involving neuropsychiatric testing, she received a diagnosis of AD 
aged 86 years. In the three years following her diagnosis, her symptoms were quite stable. 
She experienced a rapid deterioration in the last seven-eight months before her death.  
Patient F (p.H703Y) 
This patient had a strong history of cardiovascular disease and reported memory symptoms, 
aged 79, followed by irritability and anxiety and 2 years later received a clinical diagnosis of 
probable AD. Computed tomography of the brain showed supratentorial atrophy, temporal 
lobe atrophy, and slight vascular changes. The patient also experienced intermittent motor 
symptoms which included mild rigidity, tremor and slowness of movement. The MRI scans 
showed central and cortical atrophy and mild to moderate medial temporal lobe atrophy as 
well as a small old haemorrhage, ischemic lesions and  bilateral lesions localized to the 
centrum semiovale (Figure 4b). 
Patient I’s detailed description is in the supplement. 
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Tissue expression of CSF1R 
We followed-up our findings checking CSF1R expression in late onset AD and control brain 
samples. We selected entorhinal cortex (EC) and BA9 pre-association cortex (BA9) because 
the brain regions primarily affected by AD spreading pathology (Khan et al., 2014). CSF1R 
was overexpressed in AD entorhinal cortex compared to AD BA9 pre-association cortex and 
compared to control brains (Fig. 5a).  
It was not possible to quantitatively compare levels of CSF1R in all the 3 CSF1R TK mutation 
carriers due to a lack of available brain tissue. However, cDNA Sanger Sequencing revealed a 
possible allelic imbalance , with the WT allele normally expressed and the mutated one only 
moderately both  for Patient F (p.H703Y) and Patient H (p.L868R), suggesting a functional 
role of these mutations (Fig. 4g-h). RNA from entorhinal cortex and the BA9 pre-association 
cortex was available for Patient H and showed significantly lower expression of CSF1R 1) in 
entorhinal cortex compared to BA9 pre-association cortex and 2) in Patient H’s entorhinal 
cortex compared to other AD patients and controls  for all CSF1R primers tested (Fig. 5a-b). 
 
4. DISCUSSION 
 Mendelian adult-onset leukodystrophies  clinically resemble common dementias such as 
AD, potentially implying they may be influenced by shared genetic risk factors. 
To comprehensively investigate this hypothesis we applied a combination of gene 
expression analysis in different AD mouse strains at diverse developmental stages 
(http://mouseac.org/) and single-variant and single-gene based genetic screening in a 
cohort composed of 332 LOAD cases and 676 elderly controls from the UK and USA (Fig. 1). 
Divergent gene expression between AD and WT mouse strains was only detected in aged 
mice with severe core-dense plaque deposition (Fig. 2a-d, Table S3 and S4). 
Csf1r was the only gene displaying a significant differential expression between AD and WT 
mouse strains. It was up to 2 folds significantly overexpressed both in the hippocampus and 
cortex in HOTASTPM mice 8 months of age (Log2FC=1.2 and 1.1; adj p-value= 2.5E-07 and 
8.7E-05, respectively) and its overexpression linearly correlated with the rapidity of core-
dense plaque deposition rather than with their overall load (Fig2a-d, Table S3 and S4). By 
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contrast, Csf1r was downregulated when the pathology was minimal or absent (Table S3 
and S4), suggesting that Csf1r upregulation was tightly driven by and consequential to 
dense-core plaque formation and, to a lesser extent, neurofibrillary tau tangles. 
Importantly, Csf1r expression pattern relied on microglia infiltration as overexpression of 
Aif1 suggested (Fig. 2a-b, Table S3 and S4). Csf1r was co-expressed and shared the same 
expression pattern with Trem2, Tyrobp and Grn, critical genes expressed on microglia, 
whose loss of function mutation in homozygosity is causative for adult-onset 
leukodystrophies such as Polycystic lipomembranous osteodysplasia with sclerosing 
leukoencephalopathy (PLOSL) (TREM2 and TYROBP)(Paloneva et al., 1993), and in 
heterozygosity causes FTLD-TDP (GRN)(Baker et al., 2006) or is a significant risk factor for 
sporadic AD (TREM2) (Guerreiro et al., 2013) and whose overexpression is protective and 
limits AD neuropathology through a very effective clearance of Aβ plaques (GRN, 
TREM2)(Minami et al., 2014). Notably, in all the strains, Csf1r and Grn degree of expression 
correlated and this was generally one third of Tyrobp and Trem2 overall upregulation (Fig. 3, 
Table S3 and S4). This effect was not simply due to the aging process: we do not report 
significant differential expression in Csf1r, Grn, Trem2 and Tyrobp in the cortex and 
hippocampus of WT mice between 2 and 18 months of age (-0.04<Log2FC<0.2 and 
0.04<Log2FC<0.4 in hippocampus and cortex, respectively) (Table S3 and S4). Importantly, 
CSF1R, TREM2 and TYROBP have been already shown to co-interact (Otero et al., 2009) 
(https://string-db.org/).  Here, we report GRN as an additional potential key player and their 
co-expression on microglia strengthens their synergic function. Therefore, this may imply 
that CSF1R, in concert with TREM2, TYROBP and GRN plays a key role in Aβ plaque removal, 
hypothesis supported by previous literature, reporting CSF1R overexpressed in AD patients 
particularly around senile plaques and taking part to Aβ removal (Akiyama et al., 1994) 
(Murphy et al., 2000) (Mizuno et al., 2011) (Boissonneault et al., 2009) (Boissonneault et al., 
2009) 
By contrast, no differential expression of any adult-onset leukodystrophy gene was 
observed in the E15 hippocampi and in primary cortical neurons after OGD experiments 
between APPPS1 and WT strains, likely given the fact that these genes, although expressed 
in neurons,  mainly exert a critical role on microglia (TREX1, CSF1R), astrocytes (NOTCH3, 
HTRA1) and endothelial cells (NOTCH3, HTRA1, TREX1, EIF2B2, EIF2B3, 
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EIF2B5)(http://web.stanford.edu/group/barres_lab/brain_rnaseq.html), that are minimally 
present in E15 hippocampi and primary cortical neuronal cultures. 
In our discovery and validation cohorts we detected 3 rare coding variants in the TK domain 
of CSF1R in 3 late-onset AD cases, one of these neuropathologically confirmed. Moreover, 
we report 2 cases harbouring rare mutations in the TK flanking regions (aa 538-580 and aa 
911-972, encoded by exon 12 and 22, respectively), where an additional causative mutation 
for HDLS has been recently described (c.1736G>A, p.R579Q) (Ghadiri et al., 2014).  These 
variants are very likely pathogenic: cluster to highly conserved domain among homologous 
proteins and different species (average PhyloP and PhastCons scores= 2.2 and 0.6, 
respectively)(Fig. 4i-m)and have been detected only in cases. 
Moreover,  CSF1R p.L868R is a functional mutation as it was associated with a reduced 
expression of the mutated allele (Fig. 4h) and  decreased CSF1R expression in entorhinal 
cortex, a region primarily affected in AD and generally displaying CSF1R upregulation in AD 
patients (Fig 5a and b).  Importantly, a different amino acid change, clustering within the 
same codon (p.L868P) has been reported as de novo mutation, causative for HDLS 
(Rademakers et al., 2011). Remarkably, to date, any missense mutation in Mendelian gene 
domains harbouring heterozygous causative mutations for autosomal dominant disorders 
such as familial AD and FTD (APP, PSEN1, PSEN2 and MAPT) has always been reported as 
pathogenic (Table S12, http://www.molgen.ua.ac.be/ADMutations/). The only exception is 
represented by APP p.A673T, which is a very rare protective factor for AD (Jonsson et al., 
2012) . In addition, an intronic SNP in CSF1R, rs1010101, displayed a trend towards 
association (adj p-val=2E-4), in a Genome-wide association study (GWAS) performed in 
Caucasian LOAD patients (Wijsman et al., 2011), supporting CSF1R possible role in LOAD 
progression. 
CSF1R mutation carriers presented a homogeneous phenotype, closely resembling HDLS. 
First, the symptom at onset was a memory deterioration followed by behavioural changes in 
3/3 carriers. Second, the T2-weighted MRI, available for 2 patients, showed symmetric 
patchy periventricular hyperintensities, mainly pronounced in the frontal lobe (Patient E) 
and bilateral lesions localized to the centrum semiovale (Patient F)(Fig. 4b), that represent 
common MRI findings in HDLS patients (Ghadiri et al., 2014), (Rademakers et al., 2011) 
(Boissé et al., 2010) (Mateen et al., 2010). Finally, senile plaques, amyloid angiopathy and 
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tau tangles have been reported also in the cortex and hippocampus of 2 familial and one 
sporadic HDLS patients (Baba et al., 2006) (Browne et al., 2003). Importantly, these 3 HDLS 
patients displaying AD neuropathological hallmarks presented an overall early age at onset 
(average 54 years [range 78-32y]), developed Parkinsonism, atypical Parkinsonism and 
motor impairment with increasing rigidity (Table S13). By contrast, only Patient F (20%) 
displayed intermittent mild rigidity, tremor and bradykinesia, arguing for Parkinsonism, 
however within a neurological picture already dominated by cerebrovascular disorders, and 
Patient H reported no sign of motor impairment beside 2 falls in few months. Nevertheless, 
although an earlier age at onset, Parkinsonism and distinctive motor features may be more 
common in HDLS patients presenting AD neuropathology than AD cases carrying CSF1R TK 
mutations, the average disease duration for both these HDLS and AD patients was 7 years. 
Therefore, in the absence of accurate differential diagnostic criteria, this combination of 
clinical, neuroimaging and neuropathological features strikingly overlapping makes the 
definitive neurological diagnosis a real conundrum.  The fact that potentially pathogenic 
mutations in the TK domain in heterozygosity may be detected either in databases and 
apparently healthy controls or give rise to both HDLS or being rare risk factors for AD may 
be due to different factors modifying the mutation penetrance (Karle et al., 2013). 
Analogously to GRN missense mutations in AD and FTD,  CSF1R mutation penetrance may be 
influenced by APOE genotype, aging, disease duration or comorbidities such as 
cerebrovascular accidents, for which CSF1R has been already shown to play a critical 
protective role (Luo et al., 2013). In addition, It may be plausible that the majority of HDLS 
patients may not display AD neuropathology due to the rapid progression of the disease 
(Baba et al., 2006). 
Finally, NOTCH3 was a significant hit in the gene-based analysis (c-alpha test, adj p-val= 
0.01). The signal was driven both by a common synonymous variant (p.P1521P)(Table S9), 
that may influence gene expression (Sauna and Kimchi-Sarfaty, 2011) and 3 rare coding 
variants with large effect size (p.V1952M, p.V1183M, p.H170R, 2.73<0R<1.63), whose 
carrier frequency was between 2 and 3 times higher in cases compared to controls, 
although not significant (Table S6 and S10). Importantly, these rare variants (p.V1952M, 
p.V1183M, p.H170R) have been already reported to be significantly associated with severity 
of white matter lesions in elderly with hypertension (Schmidt et al., 2011), suggesting a 
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potential role as disease modifier in LOAD. In addition, we report a heterozygous pathogenic 
gain of cysteine mutation in NOTCH3 (p.R578C) detected in one control and already 
reported in a Korean patient with clinical suspicious CADASIL , implying that the penetrance 
of NOTCH3 mutations is variable (Kim et al., 2014). 
Therefore, although canonical NOTCH3 mutations causative for CADASIL are highly 
stereotyped: 1) cluster in epidermal growth factor-like repeat domains (EGFR), 2) in exon 3 
and 4 and 3) consist in the gain or loss of cysteine, nevertheless, our study reports a possible 
synergetic effect of common and rare variants in NOTCH3 potentially influencing AD 
susceptibility through an increased risk for small vessel disease or white matter lesions. Our 
hypotheses are supported by a growing body of evidence showing that 1) NOTCH3 common 
variants (rs1043994, rs10404382, rs10423702, rs1043997) are significantly associated with 
white matter lesion in elderly with hypertension (Schmidt et al., 2011) and 2) rare non-
cysteine mutations may be pathogenic as they have been reported in Korean and Japanese 
CADASIL patients, in a French case with small vessel disease and have been associated to 
severe white matter lesions in elderly patients (Mizuno et al., 2008) (Fouillade et al., 2008) 
(Schmidt et al., 2011). Importantly, our findings add evidence to the pathogenic link 
between AD and CADASIL, displaying clinical shared features and rarely, as only few cases 
have been reported, neuropathological hallmarks characterized by Aβ plaques, amyloid 
angiopathy and neurofibrillary tangles (Thijs et al., 2003) (Guerreiro et al., 2012) (Gray et al., 
1994) (Paquet et al., 2010). Biologically, presenilins cleaving both APP and NOTCH3 may 
bridge the gap between AD and CADASIL. However, whether NOTCH3 mutations or 
differential expression may accelerate a pre-existing AD or AD may contribute to CADASIL 
exacerbation remains to be elucidated. 
In summary, adult-onset Mendelian leukodystrophy genes are not common and critical 
factors in AD, therefore the genetic screening plays a pivotal role in the differential 
diagnosis. However, genetically diagnosed HDLS and CADASIL patients may display clinical, 
neuroimaging and neuropathological features meeting the diagnostic criteria for AD, leaving 
the definitive diagnosis a significant challenge. Here we report neuropathologically 
confirmed AD patients carrying likely pathogenic mutations in CSF1R TK domain and a 
potential association between AD and NOTCH3. Our study provides compelling evidence 
that HDLS, CADASIL and AD may represent shades of the same disease spectrum. Moreover, 
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we support previous studies, suggesting that CSF1R, in concert with TREM2, TYROBP and 
GRN, may play a critical role in Aβ plaque clearance and therefore may represent a pivotal, 
although rare, genetic factor influencing AD susceptibility. Given the very rare frequency of 
CSF1R TK pathogenic mutations detected in the screened patients (0.3% LOAD carriers), our 
hypotheses should foster genetic screening in larger cohorts of both early-onset and late 
onset AD cases and functional studies.  
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Figure 1  
Pipeline followed in the adult-onset leukodystrophy gene study. 
 
Figure 2. Log2 normalized expression of Csf1r, Grn, Trem2, Tyrobp and Aif1 in HOTASTPM 
mice and related Aβ plaque pathology. 
2a-b. Log2 normalized expression of Csf1r, Grn, Trem2, Tyrobp and Aif1 in HOTASTPM mice 
(homozygous for the Swedish mutation APP p.K670N/M671L and PSEN1 p.M146V) at 4 
different time points (2 months, 4 month, 8 months and 18 months) in hippocampus (2a) 
and cortex (2b) showing co-expression of the above genes. 2c-d Progression of AD 
pathology, based on Aβ plaque density, in HOTASTPM mice at 4 different time points (2 
months, 4 month, 8 months and 18 months). Significant Csf1r, Grn, Trem2, Tyrobp and Aif1 
overexpression (Log2FC>1, adj. p-val<0.05) is detected at 8 months, in linear correlation with 
the most rapid and severe Aβ plaque deposition.  
2a-d Raw data are taken from http://www.mouseac.org/    
 
Figure 3 
Log2FC of Csf1r, Grn, Trem2 and Tyrobp in different AD mouse strains during the most 
severe pathology, showing co-expression of Csf1r, Grn, Trem2 and Tyrobp. Particularly, 
Csf1r and Grn display the same overexpression pattern, which is, overall, 1/3 of Trem2 and 
Tyrobp upregulation. C, cortex; H, hippocampus. Raw data for this study are taken from 
http://www.mouseac.org/ 
Figure 4 
MRI scans, Sanger sequencing validation and mutation domain conservation for Patients E, 
F and H. 
4a-b. Coronal T2 weighted MRI scan of Patient E and F (for both taken 2y after onset of 
symptomps, aged 84y and 81y, respectively) showing symmetric patchy periventricular 
hyperintensities, mainly pronounced in the frontal lobes (4a) and bilateral lesions localized 
to the centrum semiovale (4b)(arrows). 4c-e. Genomic DNA Sanger sequencing validation of  
CSF1R c.2073G>C, c.2107C>T, c.2603 T>G mutations. 4f-h. cDNA Sanger sequencing 
validation of c.2073G>C, c.2107C>T, c.2603 T>G mutations. For patient F and H, cDNA 
sequence highlights a possible allelic imbalance, supporting the likely functional effect of 
gDNA c.2107C>T and gDNA c.2603 T>G mutations.   
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4i-m. Conservation of  p.Q691H , p. H703Y and p.L868R in different species and homologous 
proteins. PhastCons and  PhyloP  scores range between 0-1 and -14-+6, respectively. For 
PhastCons, the closer to one, the more conserved; for PhyloP, conserved sites are assigned 
positive scores.    
 
 
Figure 5. Tissue expression of CSF1R 
 
Fig5a Relative CSF1R and GAPDH expression assessed by RT-PCR in post mortem brain RNA 
from normal control and AD individuals. Fig5b Expression of CSF1R transcripts and the 
house-keeping gene GAPDH in entorhinal cortex (EC) and BA9 pre-association cortex (BA9) 
from Patient  H (c.2603T>G, p.L868R). RT-PCR for CSF1R exon 11 to 20, exon 11 to 19, exon 
17 to 20 and exon 17 to 22 as indicated. EC (entorhinal cortex); BA (Brodmann area); AD 
(Alzheimer’s disease patient); C (normal control).   
 
Figure S1 
A. Histological cortical section of APPPS1 mouse, 2 months of age, stained with amyloid β 
oligomers (Ab126892).  Rare amyloid β oligomers are detected around small cortical vessels 
(1B) and in the extracellular space, likely phagocytated by astrocytes (1C), showing a very 
mild pathology and disease state. No Aβ plaques have been detected (data not shown). 
 
Figure S2 
2a. 5´UTR lenght of the studied adult-onset leukodystrophy genes. TREX1 presents the 
longest 5´UTR region (628nts). 2b. TREX1 displays analogous 5´UTR features of BACE1, 
known to be subjected to translational control: 1) 5´UTR lenght (628 and 453nts, 
respectively); 2) GC content (65% and 77%, respectively) and 3) predicted open reading 
frames (ORFs) (6 and 3, respectively). 2cI-IV, Cortical histological sections of APPPS1 and WT 
mice (aged 2 months), stained with TREX1 antibody (Abnova 68191) which mainly binds to 
endothelial cells and to a lesser extent neurons. No macroscopical difference has been 
detected between APPPS1 and WT mice. 
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Position cDNA 
Aa  
change 
Domain ExAc EVS 
AD 
 Carriers (tot=797) 
(%) 
CTRLS  
Carrier 
(tot=676) 
MT P-value 
Adj P-
value 
OR CI 
chr5:149433682 novel p.G957R 
TK 
flanking 
region 
NA NA 1(0.12) 0 
disease
_causin
g 
1 1 Inf 0.021-Inf 
chr5:149433888 rs34030164 p.E920D 
TK 
flanking 
region 
0.003024 0.002558 2(0.25) 7(1) 
polymo
rphism 
0.089 1 0.24 0.024-1.26 
chr5:149433902 rs142435467 p.E916K 
TK 
flanking 
region 
0.000707 0.00093 0 2(0.29) 
disease
_causin
g 
0.21 1 0 0-4.5 
chr5:149434851 rs281860278 p.L868R TK 0.000089 NA 1(0.12) 0 
disease
_causin
g 
1 1 Inf 0.021-Inf 
chr5:149439287 rs111943087 p.H703Y* TK NA NA 1(0.12) 0 
polymo
rphism 
1 1 Inf 0.021-Inf 
chr5:149439315 rs545858226 p.E694K TK 0.000014 NA 0 1(0.14) 
disease
_causin
g 
0.45 1 0 0-33 
  
chr5:149439322 
novel p.Q691H* TK 0.00006 NA 1(0.12) 0 
polymo
rphism 
1 1 Inf 0.021-Inf 
chr5:149441346 novel p.D565N 
TK 
flanking 
region 
NA NA 1(0.12) 0 
disease
_causin
g 
1 1 Inf 0.021-Inf 
Table 1. Rare variants detected in CSF1R TK and TK flanking regions in the discovery and follow-up cohort (*). Aa, amino acid; tot, total; 
MT, Mutation Taster; Adj p-value, adjusted p-value, based on Bonferroni correction with 69 rare coding variants; OR, odds ratio; CI, 
confidence interval. NA, not available; Inf, infinity. 
 
Patient 
CSF1R 
mutation 
APOE AO-AD 
Family 
history of  
dementia 
disease 
duration 
First 
symptom 
Behavioural 
symptom 
Motor symp 
vascular risk 
factors 
Misdiagnosis CT/MRI Neuropath 
Patient D p.D565N 34 -92  NA NA NA NA NA NA NA NA 
Patient  E p.Q691H 34 82-89 negative 
7y, rapid 
deterioration 
during the last 
7 months 
memory 
problems 
 no   
symmetric 
patchy 
periventricular 
hyperintensities, 
mainly 
pronounced in 
the frontal lobes 
 
Patient F p.H703Y 34 79-82 negative 3y 
memory 
problems 
irritability 
and anxiety 
intermittent 
mild rigidity, 
tremor and 
bradykinesia, 
mild left 
hemiparesis 
bilateral severe 
carotid artery 
stenosis, 
vertebrobasilar 
TIA 
vascular 
dementia 
hippocampal 
and temporal 
lobe atrophy, 
subcortical  
microbleeds 
(right basal 
ganglia) and 
small ischemic 
stroke (left 
pons), lacunar 
infarct right 
parietal , 
centrum 
semiovale 
bilateral lesions 
 
Patient H p.L868R 44 64-75 
4/4 siblings 
diagnosed 
with 
dementia  
11y 
short-
term 
memory 
problems 
and 
dysphasia 
  
stroke at 65 
years 
vascular 
dementia 
severe 
microbleeding 
Extensive Aβ and 
tau deposition 
(Braak VI and 
CERAD C), amyloid 
angiopathy and 
focal TDP-43 
Patient I p.G957R NA 49-57 negative 8y 
Language 
problem 
aggression 
and paranoia 
later in the 
course of the 
disease 
no  PNFA  
Braak VI and 
CERAD C 
Table 2. CSF1R TK and TK flanking region mutation carriers description. AO-AD, age at onset-age at death; symp., symptoms; CT/MRI, 
computed tomography/magnetic resonance imaging; NA, not available; Y, years; TIA, transient ischemic attack;  PNFA, progressive 
nonfluent aphasia. 
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ADULT-ONSET MENDELIAN LEUKODYSTROPHY GENES 
(NOTCH3, TREX1, HTRA1, CSF1R, ARSA, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5)
GENETIC SCREENING ANALYSIS
SINGLE-VARIANT-BASED ANALYSIS
WHOLE-GENE -BASED ANALYSIS 
(c-alpha and SKAT test)
APPPS1
TPM
TAS10
HO_TASTPM
HET_TASTPM
TAU
HIPPOCAMPUS +CORTEX
TREX1 TRANSLATIONAL 
MODIFICATION
NIH+UCL+ADNI+BYU
332 AD CASES + 676 ELDERLY CONTROLS
EXOME and GENOME SEQUENCING
465 MCI + AD CASES
Sanger Sequencing
(p.Q691H and p.H703Y)
CSF1R FOLLOW-UP
DISCOVERY COHORTDIFFERENT DEVELOPMENTAL STAGES
DIFFERENT AD STRAINS 
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• Mendelian adult-onset leukodystrophies display clinical and, to a lesser extent, 
neuropathological and neuroimaging features overlapping with common sporadic dementias 
such as Alzheimer’s disease 
• We investigated whether this similar phenotype may have been explained by shared genetic 
risk factors 
• We report CSF1R and the synergic effect of variants in NOTCH3 as critical factors for 
Alzheimer’s disease 
